Renée Aguiar-Lucander
Independent Administrator
Renée Aguiar-Lucander is CEO of Hansa Biopharma as of April 2025. She was previously CEO of Calliditas Therapeutics, where she led the transformation of the company from a small biotech into a NASDAQ-listed, commercial-stage leader in rare diseases, culminating in its $1.1 billion acquisition by Asahi Kasei in 2024. Under her leadership, Calliditas achieved the first-ever FDA approval for a treatment in IgA nephropathy (TARPEYO®) and successfully launched the product in the U.S. market. Prior to Calliditas, she held senior roles in life sciences investment and corporate finance, including Partner and COO at Omega Fund Management and Managing Director at a global investment bank.
Renée Aguiar-Lucander holds an MBA from INSEAD and a BA in Finance from the Stockholm School of Economics.